

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/524,484	02/14/2005	Glen Ernst	100793-1P US	8633
22466 7590 10/17/2007 ASTRA ZENECA PHARMACEUTICALS LP GLOBAL INTELLECTUAL PROPERTY			EXAMINER COLEMAN, BRENDA LIBBY	
1800 CONCOR WILMINGTOR	D PIKE N, DE 19850-5437		ART UNIT	PAPER NUMBER
	•		1624	
			MAIL DATE	DELIVERY MODE
	•		10/17/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/524,484	ERNST ET AL.				
Office Action Summary	Examiner	Art Unit				
	Brenda L. Coleman	1624				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status		·				
1) Responsive to communication(s) filed on	<i>_</i> ·					
2a) This action is FINAL . 2b) This	This action is FINAL . 2b) ☐ This action is non-final.					
,	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1-15 and 19-23</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) 1-15 and 19-23 are subject to restriction and/or election requirement.						
Application Papers						
9)☐ The specification is objected to by the Examine	·г.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)⊠ All b)□ Some * c)□ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892)	r (PTO-413) ate					
3) Information Disclosure Statement(s) (PTO/SB/08) 5) Notice of Informal Patent Application						
Paper No(s)/Mail Date 6) Other:						

Application/Control Number: 10/524,484

Art Unit: 1624

DETAILED ACTION

Claims 1-15 and 19-23 are pending in the application.

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-4, 6-11, 14 and 19-21, drawn to the compounds, compositions, process of preparing and method of use of the compounds of formula I where a = 1, b = 1 and c = 1.

Group II, claim(s) 1-4, 6-11, 14 and 19-21, drawn to the compounds, compositions, process of preparing and method of use of the compounds of formula I where a = 1, b = 1 and c = 2.

Group III, claim(s) 1-15 and 19-21, drawn to the compounds, compositions, process of preparing and method of use of the compounds of formula I where a = 1, b = 2 and c = 1.

Group IV, claim(s) 1-4, 6-11, 14 and 19-21, drawn to the compounds, compositions, process of preparing and method of use of the compounds of formula I where a = 2, b = 1 and c = 1.

Group V, claim(s) 1-4, 6-11, 14 and 19-21, drawn to the compounds, compositions, process of preparing and method of use of the compounds of formula I where a = 2, b = 2 and c = 1.

Group VI, claim(s) 1-4, 6-11, 14 and 19-21, drawn to the compounds, compositions, process of preparing and method of use of the compounds of formula I where a = 2, b = 1 and c = 2.

Group VII, claim(s) 1-4, 6-11, 14 and 19-21, drawn to the compounds, compositions, process of preparing and method of use of the compounds of formula I where a = 1, b = 2 and c = 2.

Application/Control Number: 10/524,484

Art Unit: 1624

Group VIII, claim(s) 1-4, 6-11, 14 and 19-21, drawn to the compounds, compositions, process of preparing and method of use of the compounds of formula I where a = 2, b = 2 and c = 2.

Group IX, claim(s) 22 and 23, drawn to the intermediate compounds of formula VI.

The inventions listed as Groups I-VIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the inventions of Groups I-VIII are drawn to structurally dissimilar compounds, compositions and method of use of the compounds of formula I. They are made and used independently. One does not require the other for their use. If, say, the pyrrolopyrimidines of Group I, were anticipated, applicants would not acquiesce in the objection of any of the Groups II-VIII there over or vice-versa and, thus, they are not linked to the same or corresponding special technical features.

The inventions I-VIII and IX are related as mutually exclusive species in an intermediate-final product relationship. Distinctness is proven for claims in this relationship if the intermediate product is useful to make other than the final product (MPEP § 806.04(b), 3rd paragraph), and the species are patentably distinct (MPEP § 806.04(h)). In the instant case, the intermediate product is deemed to be useful to prepare other substituted bicyclic heterocycles and the inventions are deemed patentably distinct since there is nothing on this record to show them to be obvious variants.

Application/Control Number: 10/524,484

Art Unit: 1624

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Application/Control Number: 10/524,484 Page 5

Art Unit: 1624

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brenda L. Coleman whose telephone number is 571-272-0665. The examiner can normally be reached on 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Brenda L. Coleman

Primary Examiner Art Unit 1624

Friday, October 12, 2007